Search clinical trials for: Immune Globulin Subcutaneous (Human) (SCIG)

Total 886 results

CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency

Japan
Rutgers, The State University of New Jersey

Recruiting

IVIG vs SCIG in CIDP

Chronic Inflammatory Demyelinating Polyneuropathy | CIDP | Immunoglobulin Deficiency

United States
University Health Network, Toronto

Recruiting

Subcutaneous Immunoglobulin for Myasthenia Gravis (MG_SCIG)

Myasthenia Gravis

Canada
University of South Florida
CSL Behring

Completed

Subcutaneous Immunoglobulin for CIDP (SCIG)

Chronic Inflammatory Demyelinating Polyneuropathy

United States
Rochester General Hospital
Takeda

Recruiting

Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

COPD Exacerbation Acute

United States
CSL Behring

Completed

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency Disorder

Japan
Biotest Pharmaceuticals Corporation

Completed

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Liver Cirrhosis | Hepatitis, Viral, Human | Hepatocellular Carcinoma | Hepatitis C Infection | Viruses

United States
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
Baxalta now part of Shire

Completed

Immune Globulin Subcutaenous (Human), 20%

Primary Immunodeficiency Diseases (PID)

Germany, Austria, Hungary, Sweden, United Kingdom
Baxalta now part of Shire

Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Mazen Dimachkie, MD
CSL Behring

Completed

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Myasthenia Gravis

United States, Canada
Baxalta now part of Shire

Completed

Phase 2/3 Study of IGSC, 20% in PIDD

Primary Immunodeficiency Diseases (PID)

United States, Canada
Grifols Therapeutics LLC

Completed

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

Spain, France, Germany, United Kingdom, Australia, Czechia, Hungary, Poland, Sweden
Takeda
Takeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part...

Completed

A Study of TAK-881 in Healthy Adults

Healthy Volunteers

United States
Takeda
Takeda Development Center Americas, Inc.

Not yet recruiting

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)
Grifols Therapeutics LLC

Completed

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

Primary Immunodeficiency

United States
CSL Behring

Completed

Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

Primary Immune Deficiency | Secondary Immune Deficiency

Canada
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)

Primary Immunodeficiency Diseases (PID)

Canada
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)

United States
Grifols Therapeutics LLC

Recruiting

A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia

Bacterial Infections | B-cell Chronic Lymphocytic Leukemia | Hypogammaglobulinemia

United States, Bulgaria, Poland, Romania, Serbia
CSL Behring

Completed

Retrospective Chart Review of Subcutaneous IgG Use in Infants

Primary Immune Deficiency

United States
Queen Saovabha Memorial Institute

Completed

Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response

Rabies

Thailand
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection

Communicable Diseases | Healthy
Daping Hospital and the Research Institute of Surgery...

Recruiting

Intravenous Immunoglobin Transfusion in Preterm Infants With Encephalopathy of Prematurity

Preterm Infants

China
Grifols Therapeutics LLC

Completed

Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) (GamaSTAN)

Anti-Hepatitis A Antibody Levels in Heathy Subjects

United States
Green Cross Corporation
Atlantic Research Group

Completed

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

Immunologic Deficiency Syndrome

United States, Canada
Baxalta now part of Shire

Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Primary Immunodeficiency Diseases (PID)

United States
Grifols Therapeutics LLC

Completed

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

United States, Canada
University of Tennessee

Completed

Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction

Multiple Myeloma | Plasma Cell Neoplasm

United States
Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
Nabi Biopharmaceuticals

Completed

Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates

Staphylococcal Infections
National Institute of Allergy and Infectious Diseases...

Terminated

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

Kidney Failure, Chronic

United States
Baxalta now part of Shire

Terminated

Phase 3 IGIV, 10% in Alzheimer´s Disease

Alzheimer´s Disease

United States, Poland, United Kingdom, Belgium, Spain, Japan, Canada, Australia
Baxalta now part of Shire

Completed

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Primary Immunodeficiency Diseases (PID) | Immune Thrombocytopenic Purpura (ITP) | Kawasaki Syndrome

United States
Inova Health Care Services
CSL Behring

Withdrawn

IVIG in Acute Ischemic Stroke: A Pilot Study (IVIG/AIS)

Ischemic Stroke

United States
The Methodist Hospital Research Institute
Grifols Biologicals, LLC

Recruiting

Survey of Human Rabies Immune Globulin Safety in Children

Rabies | Rabies Human | Pediatrics | Rabies Virus Infection

United States
Synermore Biologics Co., Ltd.
inVentiv Health Clinical

Completed

A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines (RabiesMab)

Human Rabies

United States
Emergent BioSolutions

Completed

Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

Zika Virus Infection | Zika Virus Disease

Canada
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Healthy Volunteers

United States
Nabi Biopharmaceuticals

Completed

Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever

Staphylococcal Infections
Emergent BioSolutions
Centers for Disease Control and Prevention

Enrolling by invitation

VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection

Complication of Smallpox Vaccination
Baxalta now part of Shire

Completed

Gammagard Liquid and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States, Canada
FFF Enterprises
OMRIX Biopharmaceuticals

Completed

A Clinical Study of Intravenous Immunoglobulin (IGIV)

Immunologic Deficiency Syndromes

United States, Canada
Biotest
Syneos Health

Completed

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Primary Immunodeficiency Disease

United States, Germany, Hungary, Russian Federation, Spain
Green Cross Corporation
Parexel; Atlantic Research Group

Completed

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Immunologic Deficiency Syndromes

Canada, United States
ADMA Biologics, Inc.

Completed

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Primary Immune Deficiency Disorders (PIDD)

United States
Green Cross Corporation
Atlantic Research Group

Recruiting

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Primary Immune Deficiency

United States
Grifols Therapeutics LLC

Completed

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Common Variable Immunodeficiency | Severe Combined Immunodeficiency | Wiskott-Aldrich Syndrome | Agammaglobulinemia | Immunologic Deficiency Syndrome

Canada, United States
ADMA Biologics, Inc.

Terminated

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

Transplantation Infection | Evidence of Liver Transplantation | Sequelae of Viral Hepatitis

United States

Search clinical trials for: Immune Globulin Subcutaneous (Human) (SCIG)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations